herv-e tcr transduced cd8+/cd34+ t cells in hlaa* 11:01 positive patients
Cell therapyexperimental
Clinical trial activity
5 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jul 20, 2018 (NCT03354390)
Timeline
Indications
Mechanism of action
- Unspecified targetImmunity, passive
immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06872333 | Phase 2 | Nov 19, 2024 | University of Minnesota |
| NCT06412497 | Phase 2 | Jun 5, 2024 | University of Minnesota |
| NCT06090864 | Phase 1/Phase 2 (Phase 2) | Jan 31, 2024 | University of North Carolina at Chapel Hill |
| NCT03354390 | Phase 1 | Jul 20, 2018 | Loyola University, National Heart, Lung, and Blood Institute (NHLBI) |
| NCT05389514 | N/A | — | Providence Health & Services |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Minnesota | Academic/Hospital | 2 | 2 | 1 | 2024 |
| Loyola University | Academic/Hospital | 1 | 0 | 1 | 2018 |
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 1 | 1 | 1 | 2018 |
| Providence Health & Services | Academic/Hospital | 1 | 1 | 1 | — |
| University of North Carolina at Chapel Hill | Academic/Hospital | 1 | 1 | 1 | 2024 |
5 organizations
Page 1 / 1